Grace Therapeutics (NASDAQ:GRCE) Earns Buy Rating from HC Wainwright
Grace Therapeutics (NASDAQ:GRCE – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 259.28% from the stock’s current price. Grace Therapeutics Stock Performance […]
More Stories
Oil Prices Drop by 7 Percent as Market’s Iran Fear Factor Fades
By Andrew Moran Crude oil prices plummeted by more than 7 percent on June 23 as investors were optimistic that...
Trump Says Iran Gave US Notice Before Attacking Base in Qatar
By Ryan Morgan President Donald Trump, in a social media post on June 23, indicated Iran gave advanced warning of...
Game 7: Thunder Beat Pacers 103–91 for NBA Title
By The Associated Press OKLAHOMA CITY—Shai Gilgeous-Alexander walked off the court for the final time this season, collapsed into the...
US Manufacturing Output, Hiring Rise to Multi-Month Highs
By Tom Ozimek U.S. manufacturing activity climbed in June, fueled by strong domestic demand and tariff-driven stockpiling, according to a...
White House Warns Iran, Says Closing Hormuz Strait ‘Would Be Foolish’
By Ryan Morgan and Joseph Lord The White House has warned Iran against closing the Strait of Hormuz in response...
Garde Capital Inc. Takes $34,000 Position in Adobe Inc. (NASDAQ:ADBE)
Garde Capital Inc. acquired a new stake in Adobe Inc. (NASDAQ:ADBE – Free Report) during the first quarter, according to...